Literature DB >> 2989659

Passive immunization of mice with monoclonal antibodies to glycoprotein gB of herpes simplex virus.

Y Kino, T Eto, N Ohtomo, Y Hayashi, M Yamamoto, R Mori.   

Abstract

To investigate the protective ability of monoclonal antibodies (MCAs) to viral glycoprotein in herpes simplex virus (HSV) infection, athymic nude mice were inoculated intracutaneously with HSV type-1 (HSV-1) in the midflank. Three hours after inoculation, one group of mice was passively immunized with one of a series of MCAs to glycoprotein gB of HSV-1, and a control group of mice was given phosphate buffered saline alone. The control mice died within 16 days after infection, whereas the mice passively immunized with any of the MCA showed suppressed development of skin lesions. Three of six mice given MCA failed to develop any visible lesions and no HSV could be isolated from the lumbar dorsal root ganglia of these mice 60 days after the challenge. BALB/c mice were also protected from infection with HSV type 2 by passive immunization with MCA to HSV-1 gB.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989659     DOI: 10.1111/j.1348-0421.1985.tb00812.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  8 in total

1.  Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity.

Authors:  Chaya D Patel; Iara M Backes; Sean A Taylor; Yike Jiang; Arnaud Marchant; Jean M Pesola; Donald M Coen; David M Knipe; Margaret E Ackerman; David A Leib
Journal:  Sci Transl Med       Date:  2019-04-10       Impact factor: 17.956

2.  Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity.

Authors:  Chaya D Patel; Sean A Taylor; Jesse Mehrbach; Sita Awasthi; Harvey M Friedman; David A Leib
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

3.  Immunogenicity of purified glycoprotein gB of herpes simplex virus.

Authors:  Y Kino; T Eto; K Nishiyama; N Ohtomo; R Mori
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

4.  Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector.

Authors:  R Manservigi; M P Grossi; R Gualandri; P G Balboni; A Marchini; A Rotola; P Rimessi; D Di Luca; E Cassai; G Barbanti-Brodano
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

5.  Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B.

Authors:  S Kohl; N C Strynadka; R S Hodges; L Pereira
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

6.  Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2.

Authors:  M Bröker; K J Abel; R Köhler; J Hilfenhaus; E Amann
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

7.  Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.

Authors:  E M Cantin; R Eberle; J L Baldick; B Moss; D E Willey; A L Notkins; H Openshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 8.  Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections.

Authors:  Iara M Backes; David A Leib; Margaret E Ackerman
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.